In summary, CRISPR/Cas9 genome-edited TGFBRII leads to the blocking of TGF-β signaling pathways in advanced prostate cancer cells, triggering positive feedback activation of ERK that uncouples malignant cell growth and metastasis capability in a xenograft mouse model. The gene discussed is TGFB1; the disease is prostate carcinoma.